Immunotherapy Bridge 2020 and Melanoma Bridge 2020: meeting abstracts

Table 1 (Abstract 7) Clinical biomarkers of response to anti-PD-1 and progression free survival. This Table 1 belongs to Abstract 7

	Univariate		Multivariate*
	Types of Melanoma (cutaneous, mucosal, uveal)		Types of Melanoma (cutaneous, mucosal, uveal)
	Crude HR (95%CI)	P	Adjusted HR (95%CI)	P
ECOG performance status
0	1		1
1	2.13 (1.09–4.16)	0.026	2.67 (1.30–5.52)	0.008
≥ 2	3.08 (1.56–6.05)	0.001	2.21 (1.06–4.63)	0.035
Stages of metastasis
1a-1b	1		1
1c	1.88 (1.04–3.38)	0.036	1.80 (0.95–3.41)	0.074
1d	3.18 (1.66–6.08)	< 0.0001	2.92 (1.38–6.18)	0.005
LDH serum
Normal	1		1
High	2.32 (1.34–4.01)	0.003	2.09 (1.16–3.75)	0.014

HR, Hazard Ratio; CI, Confidence Interval
* the estimates are adjusted for gender, age, ECOG PS, stage of metastasis and LDH levels

ISSN: 1479-5876